No abstract

Summary Forty-five patients with relapsed or refractory multiple myeloma received continuous infusions of vincristine (0.4mg total dose daily for 4 days) and adriamycin (9mgm-2 daily for 4 days) with a high dose of methylprednisolone (1 gm-2 i.v. or p.o. daily by 1 h infusion), the VAMP regimen. Sixteen (36%) responded, with a median duration of remission of 11 months and median survival of 20 months. Major toxicities encountered were infective and cardiovascular. Two smaller groups of myeloma patients were treated with high dose methylprednisolone (HDMP) alone, or VAMP plus weekly low dose cyclophosphamide (Cyclo-VAMP). HDMP produced short responses in 25% of patients with less toxicity than VAMP. Cyclo-VAMP was used in a highly selected group of patients who had previously responded to high dose melphalan. It was well tolerated and produced responses in 61 % of this group.